Cone Health Gram Negatives		Percent Susceptible														
Organism	Isolates	Gent	Tobra	lmi	Cefazolin	Cefepime	Ceftaz	Ceftriax	Amp	Amp/Sul	Pip/tazo	Cipro	Levo	Nitro*	TMP/SMZ	
Acinetobacter calco/baum	65	57%	66%	47%		32%		8%		49%	50%	31%	37%	0%	39%	
Citrobacter freundii	100	98%	97%	100%			89%	78%			83%	90%	92%	92%	91%	
Citrobacter koseri	95	98%	98%	100%	97%	100%	100%	100%			98%	96%	96%	48%	97%	
Enterobacter aerogenes	149	94%	94%	100%		87%		80%			75%	99%	99%	6%	100%	
Enterobacter cloacae	188	95%	95%	95%		97%		74%			69%	89%	89%	18%	88%	
Escherichia coli	5687	93%	94%	100%	91%			96%	51%	51%	96%	80%	81%	90%	77%	
Klebsiella oxytoca	73	100%	97%	100%	77%	100%	100%	97%		69%	92%	93%	91%		99%	
Klebsiella pneumoniae	1086	96%	94%	98%	87%	91%	91%	93%		85%	92%	92%	92%	27%	89%	
Morganella morganii	63	92%	94%	100%	2%			94%			94%	81%	81%		76%	
Proteus mirabilis	595	86%	90%	86%	93%	99%	99%	98%	88%	92%	100%	74%	75%		83%	
Pseudomonas aeruginosa	481	89%	94%	81%		86%	86%				87-93%**	71%				
Serratia marcescens	86	100%	88%	100%	0%	100%	100%	100%			100%	97%	96%		100%	
Stenotrophomonas maltophilia	36												69%		83%	

Blank spaces indicate insufficient data

Cone Health Gram Positives			Percent Susceptible														
Organism	Isolates	Gent	Ceftriax	Amp	Оха	PCN	Levo	Мохі	Clinda	Erythro	Gent synergy	Linezolid	Nitro*	Rif	Tetra	TMP/ SMZ	Vanco
Enterococcus species (VRE excluded)	775			95%			70%				87%		81%		25%		100%
Enterococcus VRE only	102			14%			1%				80%	95%	21%		4%		0%
Staphylococcus aureus MSSA	829	100%			100%	21%	80%	81%	83%	65%			99%	99%	93%	97%	100%
Staphylococcus aureus MRSA	860	99%			0%	0%	28%		75%	11%			97%	99%	93%	96%	100%
Staphylococcus coag negative	668	93%			49%	8%	78%		64%	33%			98%	99%	81%	72%	100%
Streptococcus agalactiae group B	59			100%		100%	99%		71%	53%							100%
Streptococcus group D	50					98%											
Streptococcus pneumoniae	62		90%			56%	97%										

Blank spaces indicate insufficient data

51% of S. aureus isolates are oxacillin resistant

^{*} Urinary isolates only

^{**}Susceptability data for piperacillin/tazobactam against Pseudomonas aeruginosa for 2014 is reported as a range due to changes in testing requirements for resistant isolates

^{*} urinary isolates only